

**FOR IMMEDIATE RELEASE**

Listed Company Name: Kyowa Hakko Kirin Co., Ltd.

Representative: Nobuo Hanai, President and CEO

(Code no.: 4151, First Section of TSE)

Inquiries: Shigeru Morotomi, Managing Officer

Corporate Communications Department

Telephone: +81-3-3282-0009

## Notice of revisions to the Appendix to the Fiscal 2013 First Quarter Consolidated Financial Statements issued on April 24, 2013

Consolidated figures for Trends in results by segment in the Appendix to the Fiscal 2013 First Quarter Consolidated Financial Statements have been revised as follows. Amended figures have been underlined.

Page 2: Section I. Consolidated Financial Results,

2. Trends in results by segment

**Before revision**

Accumulative

|                                      | FY 2013 results |               |            |
|--------------------------------------|-----------------|---------------|------------|
|                                      | Jan - Mar       | Change Amount | Change %   |
| Operating income                     | 14.4            | (3.5)         | 80%        |
| <i>*Before goodwill amortization</i> | <u>17.2</u>     | <u>(3.1)</u>  | <u>85%</u> |
| Pharmaceuticals                      | 13.0            | (3.6)         | 78%        |
| Bio-Chemicals                        | 1.4             | 0.1           | 114%       |
| Total                                | 14.5            | (3.4)         | 81%        |
| Eliminations                         | (0.0)           | (0.0)         | -          |

**After revision**

Accumulative

|                                      | FY 2013 results |               |            |
|--------------------------------------|-----------------|---------------|------------|
|                                      | Jan - Mar       | Change Amount | Change %   |
| Operating income                     | 14.4            | (3.5)         | 80%        |
| <i>*Before goodwill amortization</i> | <u>16.7</u>     | <u>(3.5)</u>  | <u>82%</u> |
| Pharmaceuticals                      | 13.0            | (3.6)         | 78%        |
| Bio-Chemicals                        | 1.4             | 0.1           | 114%       |
| Total                                | 14.5            | (3.4)         | 81%        |
| Eliminations                         | (0.0)           | (0.0)         | -          |

Quarterly

|                                      | FY 2013 results |               |            |
|--------------------------------------|-----------------|---------------|------------|
|                                      | Jan - Mar       | Change Amount | Change %   |
| Operating income                     | 14.4            | (3.5)         | 80%        |
| <i>*Before goodwill amortization</i> | <u>17.2</u>     | <u>(3.1)</u>  | <u>85%</u> |
| Pharmaceuticals                      | 13.0            | (3.6)         | 78%        |
| Bio-Chemicals                        | 1.4             | 0.1           | 114%       |
| Total                                | 14.5            | (3.4)         | 81%        |
| Eliminations                         | (0.0)           | (0.0)         | -          |

Quarterly

|                                      | FY 2013 results |               |            |
|--------------------------------------|-----------------|---------------|------------|
|                                      | Jan - Mar       | Change Amount | Change %   |
| Operating income                     | 14.4            | (3.5)         | 80%        |
| <i>*Before goodwill amortization</i> | <u>16.7</u>     | <u>(3.5)</u>  | <u>82%</u> |
| Pharmaceuticals                      | 13.0            | (3.6)         | 78%        |
| Bio-Chemicals                        | 1.4             | 0.1           | 114%       |
| Total                                | 14.5            | (3.4)         | 81%        |
| Eliminations                         | (0.0)           | (0.0)         | -          |

\*\*\*ENDS\*\*\*

For further information please access: [http://www.kyowa-kirin.com/news\\_releases/index.html](http://www.kyowa-kirin.com/news_releases/index.html)

# Kyowa Hakko Kirin Co., Ltd.

## Appendix to the Fiscal 2013 First Quarter Consolidated Financial Statements

First quarter results for Fiscal 2013  
(January 1, 2013 - March 31, 2013)

| Index  | Page  |
|--|-------|
| I. Consolidated Financial Results                                      |       |
| 1. Trends in consolidated income                                       | 1     |
| 2. Trends in results by segment  | 2     |
| 3. Other trends  | 3     |
| II. Consolidated Subsidiaries and Affiliates                           | 4     |
| III. Kyowa Hakko Kirin Sales of main products                          |       |
| Accumulative   | 5     |
| Quarterly  | 6     |
| IV. Segment information and main subsidiaries operating profit or loss |       |
| 1. Pharmaceuticals segment   | 7     |
| 2. Bio-Chemicalss segment  | 8     |
| R&D Pipeline   | 9, 10 |

- This document was made as a supplement to the Kessan Tanshin (financial report) for the first quarter of Fiscal 2013, the three-month period from January 1, 2013 to March 31, 2013.
- This document contains forward-looking statements based on a member of assumptions and beliefs made by management in light of information currently available. For a variety of reasons, actual financial results may differ materially from the forecasts presented here.
- Figures presented in this document have been rounded down to the nearest whole number.
- The average exchange rate for each period was as follows.

Unit: yen

|       | 2012 results |           |           |           | 2013 results |           |           |           | 2013 forecasts |           |
|-------|--------------|-----------|-----------|-----------|--------------|-----------|-----------|-----------|----------------|-----------|
|       | Jan - Mar    | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar    | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Jun      | Jan - Dec |
| US \$ | 79           | 80        | 79        | 80        | 89           | -         | -         | -         | 85             | 85        |
| Euro  | 104          | 103       | 102       | 103       | 118          | -         | -         | -         | 115            | 115       |
| GBP   | 125          | 126       | 125       | 127       | 141          | -         | -         | -         | 140            | 140       |

Contact  
 Kyowa Hakko Kirin Co., Ltd.  
 Corporate Communications Department  
 Tel 81 3 3282 0009

## I. Consolidated Financial Results

### 1. Trends in consolidated income

Accumulative

Billions of yen, rounded down

|  | FY 2012 results |           |           |           | FY 2013 results |               |          |           |          |           |          |           | FY 2013 forecasts |           |          |           |          |
|--|-----------------|-----------|-----------|-----------|-----------------|---------------|----------|-----------|----------|-----------|----------|-----------|-------------------|-----------|----------|-----------|----------|
|  | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Change Amount | Change % | Jan - Jun | Change % | Jan - Sep | Change % | Jan - Dec | Change %          | Jan - Jun | Change % | Jan - Dec | Change % |
| Net sales  | 87.1            | 166.2     | 244.6     | 333.1     | 86.6            | (0.4)         | 99%      | -         | -        | -         | -        | -         | -                 | 169.0     | 102%     | 338.0     | 101%     |
| Gross Profit   | 55.0            | 104.3     | 154.3     | 210.6     | 52.3            | (2.6)         | 95%      | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Selling, general and administrative expenses         | 36.9            | 78.7      | 117.0     | 157.7     | 37.8            | 0.9           | 102%     | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Operating income (Prior to amortization of goodwill) | 20.3            | 30.2      | 44.2      | 62.1      | 16.7            | (3.5)         | 82%      | -         | -        | -         | -        | -         | -                 | 33.6      | 111%     | 64.2      | 103%     |
| Operating income                                     | 18.0            | 25.5      | 37.3      | 52.9      | 14.4            | (3.5)         | 80%      | -         | -        | -         | -        | -         | -                 | 29.0      | 113%     | 55.0      | 104%     |
| Other income   | 1.6             | 1.4       | 1.9       | 4.1       | 1.0             | (0.6)         | 63%      | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Other expenses                                       | 3.1             | 3.9       | 6.6       | 8.0       | 0.6             | (2.4)         | 22%      | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Ordinary income                                      | 16.5            | 23.0      | 32.5      | 49.0      | 14.8            | (1.7)         | 90%      | -         | -        | -         | -        | -         | -                 | -         | -        | 49.0      | 100%     |
| Extraordinary income                                 | -               | -         | -         | -         | 3.8             | 3.8           | -        | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Extraordinary expenses                               | 0.3             | 0.3       | 1.2       | 3.9       | -               | (0.3)         | -        | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Net income before income taxes                       | 16.2            | 22.7      | 31.3      | 45.0      | 18.6            | 2.4           | 115%     | -         | -        | -         | -        | -         | -                 | -         | -        | 52.0      | 115%     |
| Corporate, local and enterprise taxes                | 7.7             | 11.2      | 15.8      | 20.6      | 8.1             | 0.4           | 106%     | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Income from minority interests                       | 0.0             | 0.0       | 0.0       | 0.2       | 0.0             | (0.0)         | 52%      | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Net income   | 8.5             | 11.5      | 15.4      | 24.1      | 10.4            | 1.9           | 123%     | -         | -        | -         | -        | -         | -                 | -         | -        | 30.0      | 124%     |
| Comprehensive income                                 | 15.0            | 13.3      | 18.3      | 34.7      | 16.8            | 1.7           | 112%     | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| EPS prior to amortization of goodwill (¥/share)      | 19.66           | 29.40     | 40.79     | 61.00     | 23.39           | 3.73          | 119%     | -         | -        | -         | -        | -         | -                 | -         | -        | 71.71     | 118%     |

\*1 "Prior to amortization of goodwill" refers to profits prior to the deduction of amortization of the goodwill arising on the reverse acquisition in April 2008 (Kirin Pharma share transfer).  
(Note: This adjustment does not include goodwill amortization in respect of the acquisition of ProStrakan.)

\*2 There are no changes to the consolidated results forecasts for the fiscal year ending December 31, 2013 announced on January 31, 2013.

### Quarterly

Billions of yen, rounded down

|  | FY 2012 results |           |           |           | FY 2013 results |               |          |           |          |           |          |           | FY 2013 forecasts |           |          |           |          |
|--|-----------------|-----------|-----------|-----------|-----------------|---------------|----------|-----------|----------|-----------|----------|-----------|-------------------|-----------|----------|-----------|----------|
|  | Jan - Mar       | Apr - Jun | Jul - Sep | Oct - Dec | Jan - Mar       | Change Amount | Change % | Apr - Jun | Change % | Jul - Sep | Change % | Oct - Dec | Change %          | Jan - Jun | Change % | Jul - Dec | Change % |
| Net sales  | 87.1            | 79.1      | 78.4      | 88.4      | 86.6            | (0.4)         | 99%      | -         | -        | -         | -        | -         | -                 | 169.0     | 102%     | 169.0     | 101%     |
| Gross Profit   | 55.0            | 49.3      | 50.0      | 56.3      | 52.3            | (2.6)         | 95%      | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Selling, general and administrative expenses         | 36.9            | 41.7      | 38.3      | 40.7      | 37.8            | 0.9           | 102%     | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Operating income (Prior to amortization of goodwill) | 20.3            | 9.8       | 14.0      | 17.8      | 16.7            | (3.5)         | 82%      | -         | -        | -         | -        | -         | -                 | 33.6      | 111%     | 30.6      | 96%      |
| Operating income                                     | 18.0            | 7.5       | 11.7      | 15.5      | 14.4            | (3.5)         | 80%      | -         | -        | -         | -        | -         | -                 | 29.0      | 113%     | 26.0      | 95%      |
| Other income   | 1.6             | (0.2)     | 0.5       | 2.2       | 1.0             | (0.6)         | 63%      | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Other expenses                                       | 3.1             | 0.7       | 2.7       | 1.3       | 0.6             | (2.4)         | 22%      | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Ordinary income                                      | 16.5            | 6.5       | 9.4       | 16.4      | 14.8            | (1.7)         | 90%      | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Extraordinary income                                 | -               | -         | -         | -         | 3.8             | 3.8           | -        | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Extraordinary expenses                               | 0.3             | -         | 0.9       | 2.7       | -               | (0.3)         | -        | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Net income before income taxes                       | 16.2            | 6.5       | 8.5       | 13.6      | 18.6            | 2.4           | 115%     | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Corporate, local and enterprise taxes                | 7.7             | 3.4       | 4.6       | 4.7       | 8.1             | 0.4           | 106%     | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Income from minority interests                       | 0.0             | 0.0       | 0.0       | 0.1       | 0.0             | (0.0)         | 52%      | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| Net income   | 8.5             | 3.0       | 3.9       | 8.7       | 10.4            | 1.9           | 123%     | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |
| EPS prior to amortization of goodwill (¥/share)      | 19.66           | 9.72      | 11.38     | 20.23     | 23.39           | 3.73          | 119%     | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |

**I. Consolidated Financial Results**

**2. Trends in results by segment**

**Accumulative**

Billions of yen, rounded down

|                               | FY 2012 results |           |           |           | FY 2013 results |               |          |           |          |           |          |           | FY 2013 forecasts |           |          |           |          |
|-------------------------------|-----------------|-----------|-----------|-----------|-----------------|---------------|----------|-----------|----------|-----------|----------|-----------|-------------------|-----------|----------|-----------|----------|
|                               | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Change Amount | Change % | Jan - Jun | Change % | Jan - Sep | Change % | Jan - Dec | Change %          | Jan - Jun | Change % | Jan - Dec | Change % |
| Net sales                     | 87.1            | 166.2     | 244.6     | 333.1     | 86.6            | (0.4)         | 99%      | -         | -        | -         | -        | -         | -                 | 169.0     | 102%     | 338.0     | 101%     |
| Pharmaceuticals               | 67.2            | 127.5     | 189.4     | 259.3     | 67.4            | 0.2           | 100%     | -         | -        | -         | -        | -         | -                 | 130.0     | 102%     | 260.0     | 100%     |
| Bio-Chemicals                 | 20.5            | 40.0      | 57.4      | 76.9      | 19.9            | (0.5)         | 97%      | -         | -        | -         | -        | -         | -                 | 40.0      | 100%     | 81.0      | 105%     |
| Total                         | 87.8            | 167.6     | 246.9     | 336.3     | 87.4            | (0.3)         | 100%     | -         | -        | -         | -        | -         | -                 | 170.0     | 101%     | 341.0     | 101%     |
| Eliminations                  | (0.6)           | (1.3)     | (2.2)     | (3.1)     | (0.7)           | (0.0)         | -        | -         | -        | -         | -        | -         | -                 | (1.0)     | -        | (3.0)     | -        |
| Operating income              | 18.0            | 25.5      | 37.3      | 52.9      | 14.4            | (3.5)         | 80%      | -         | -        | -         | -        | -         | -                 | 29.0      | 113%     | 55.0      | 104%     |
| *Before goodwill amortization | 20.3            | 30.2      | 44.2      | 62.1      | 16.7            | (3.5)         | 82%      | -         | -        | -         | -        | -         | -                 | 33.6      | 111%     | 64.2      | 103%     |
| Pharmaceuticals               | 16.7            | 23.5      | 35.1      | 50.7      | 13.0            | (3.6)         | 78%      | -         | -        | -         | -        | -         | -                 | 25.6      | 109%     | 49.2      | 97%      |
| 18.8                          | 27.8            | 41.5      | 59.3      | 15.2      | (3.6)           | 81%           | -        | -         | -        | -         | -        | -         | 29.9              | 107%      | 57.8     | 97%       |          |
| Bio-Chemicals                 | 1.3             | 2.0       | 2.2       | 2.1       | 1.4             | 0.1           | 114%     | -         | -        | -         | -        | -         | -                 | 3.4       | 167%     | 5.8       | 273%     |
| 1.4                           | 2.3             | 2.6       | 2.7       | 1.6       | 0.1             | 112%          | -        | -         | -        | -         | -        | -         | 3.7               | 158%      | 6.4      | 233%      |          |
| Total                         | 18.0            | 25.5      | 37.3      | 52.8      | 14.5            | (3.4)         | 81%      | -         | -        | -         | -        | -         | -                 | 29.0      | 113%     | 55.0      | 104%     |
| 20.3                          | 30.1            | 44.2      | 62.1      | 16.8      | (3.4)           | 83%           | -        | -         | -        | -         | -        | -         | 33.6              | 111%      | 64.2     | 103%      |          |
| Eliminations                  | 0.0             | 0.0       | 0.0       | 0.0       | (0.0)           | (0.0)         | -        | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |

\*The Other segment has been discontinued from 2013. As a result figures for 2012 results and 2013 forecasts have been restated in accordance with the 2013 revised segmental classification.

**Quarterly**

Billions of yen, rounded down

|                               | FY 2012 results |           |           |           | FY 2013 results |               |          |           |          |           |          |           | FY 2013 forecasts |           |          |           |          |
|-------------------------------|-----------------|-----------|-----------|-----------|-----------------|---------------|----------|-----------|----------|-----------|----------|-----------|-------------------|-----------|----------|-----------|----------|
|                               | Jan - Mar       | Apr - Jun | Jul - Sep | Oct - Dec | Jan - Mar       | Change Amount | Change % | Apr - Jun | Change % | Jul - Sep | Change % | Oct - Dec | Change %          | Jan - Jun | Change % | Jul - Dec | Change % |
| Net sales                     | 87.1            | 79.1      | 78.4      | 88.4      | 86.6            | (0.4)         | 99%      | -         | -        | -         | -        | -         | -                 | 169.0     | 102%     | 169.0     | 101%     |
| Pharmaceuticals               | 67.2            | 60.3      | 61.8      | 69.8      | 67.4            | 0.2           | 100%     | -         | -        | -         | -        | -         | -                 | 130.0     | 102%     | 130.0     | 99%      |
| Bio-Chemicals                 | 20.5            | 19.4      | 17.4      | 19.4      | 19.9            | (0.5)         | 97%      | -         | -        | -         | -        | -         | -                 | 40.0      | 100%     | 41.0      | 111%     |
| Total                         | 87.8            | 79.8      | 79.3      | 89.3      | 87.4            | (0.3)         | 100%     | -         | -        | -         | -        | -         | -                 | 170.0     | 101%     | 171.0     | 101%     |
| Eliminations                  | (0.6)           | (0.6)     | (0.9)     | (0.8)     | (0.7)           | (0.0)         | -        | -         | -        | -         | -        | -         | -                 | (1.0)     | -        | (2.0)     | -        |
| Operating income              | 18.0            | 7.5       | 11.7      | 15.5      | 14.4            | (3.5)         | 80%      | -         | -        | -         | -        | -         | -                 | 29.0      | 113%     | 26.0      | 95%      |
| *Before goodwill amortization | 20.3            | 9.8       | 14.0      | 17.8      | 16.7            | (3.5)         | 82%      | -         | -        | -         | -        | -         | -                 | 33.6      | 111%     | 30.6      | 96%      |
| Pharmaceuticals               | 16.7            | 6.7       | 11.5      | 15.6      | 13.0            | (3.6)         | 78%      | -         | -        | -         | -        | -         | -                 | 25.6      | 109%     | 23.6      | 87%      |
| 18.8                          | 8.9             | 13.7      | 17.7      | 15.2      | (3.6)           | 81%           | -        | -         | -        | -         | -        | -         | 29.9              | 107%      | 27.9     | 89%       |          |
| Bio-Chemicals                 | 1.3             | 0.7       | 0.1       | 0.0       | 1.4             | 0.1           | 114%     | -         | -        | -         | -        | -         | -                 | 3.4       | 167%     | 2.4       | -        |
| 1.4                           | 0.8             | 0.3       | 0.0       | 1.6       | 0.1             | 112%          | -        | -         | -        | -         | -        | -         | 3.7               | 158%      | 2.7      | 678%      |          |
| Total                         | 18.0            | 7.5       | 11.7      | 15.5      | 14.5            | (3.4)         | 81%      | -         | -        | -         | -        | -         | -                 | 29.0      | 113%     | 26.0      | 95%      |
| 20.3                          | 9.8             | 14.0      | 17.8      | 16.8      | (3.4)           | 83%           | -        | -         | -        | -         | -        | -         | 33.6              | 111%      | 30.6     | 96%       |          |
| Eliminations                  | 0.0             | 0.0       | 0.0       | 0.0       | (0.0)           | (0.0)         | -        | -         | -        | -         | -        | -         | -                 | -         | -        | -         | -        |

**(2) Regional sales**

Billions of yen, rounded down

|                              | FY 2012 results |                                  |           |                                  | FY 2013 results |                                  |           |                                  |           |                                  |           |                                  |           |                                  |           |                                  |
|------------------------------|-----------------|----------------------------------|-----------|----------------------------------|-----------------|----------------------------------|-----------|----------------------------------|-----------|----------------------------------|-----------|----------------------------------|-----------|----------------------------------|-----------|----------------------------------|
|                              | Jan - Mar       | Percentage of consolidated sales | Jan - Jun | Percentage of consolidated sales | Jan - Sep       | Percentage of consolidated sales | Jan - Dec | Percentage of consolidated sales | Jan - Mar | Percentage of consolidated sales | Jan - Jun | Percentage of consolidated sales | Jan - Sep | Percentage of consolidated sales | Jan - Dec | Percentage of consolidated sales |
| Japan sales                  | 68.9            | 79.1%                            | 128.8     | 77.5%                            | 189.9           | 77.6%                            | 260.5     | 78.2%                            | 66.1      | 76.3%                            | -         | -                                | -         | -                                | -         | -                                |
| Overseas sales               | 18.1            | 20.9%                            | 37.3      | 22.5%                            | 54.7            | 22.4%                            | 72.6      | 21.8%                            | 20.5      | 23.7%                            | -         | -                                | -         | -                                | -         | -                                |
| America                      | 4.6             | 5.3%                             | 10.0      | 6.1%                             | 15.0            | 6.2%                             | 21.2      | 6.4%                             | 5.2       | 6.0%                             | -         | -                                | -         | -                                | -         | -                                |
| Europe                       | 8.4             | 9.7%                             | 16.9      | 10.2%                            | 24.0            | 9.8%                             | 30.9      | 9.3%                             | 9.4       | 10.9%                            | -         | -                                | -         | -                                | -         | -                                |
| Asia                         | 4.9             | 5.7%                             | 10.0      | 6.1%                             | 15.2            | 6.2%                             | 19.8      | 6.0%                             | 5.7       | 6.6%                             | -         | -                                | -         | -                                | -         | -                                |
| Other regions                | 0.1             | 0.1%                             | 0.2       | 0.2%                             | 0.4             | 0.2%                             | 0.5       | 0.2%                             | 0.1       | 0.2%                             | -         | -                                | -         | -                                | -         | -                                |
| Total consolidated net sales | 87.1            | 100.0%                           | 166.2     | 100.0%                           | 244.6           | 100.0%                           | 333.1     | 100.0%                           | 86.6      | 100.0%                           | -         | -                                | -         | -                                | -         | -                                |

\* Sales classified by region or country based on location of customer.

## I. Consolidated Financial Results

### 3. Other trends

#### (1) R&D Expenses

Billions of yen, rounded down

|                                   | FY 2012 results |           |           |           | FY 2013 results |           |           |           | FY 2013 forecasts |           |
|-----------------------------------|-----------------|-----------|-----------|-----------|-----------------|-----------|-----------|-----------|-------------------|-----------|
|                                   | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Jun         | Jan - Dec |
| R&D expenses                      | 11.0            | 22.1      | 33.6      | 44.8      | 10.6            | -         | -         | -         | 22.2              | 44.0      |
| <i>R&amp;D to net sales ratio</i> | 12.7%           | 13.3%     | 13.8%     | 13.4%     | 12.3%           | -         | -         | -         | 13.2%             | 13.0%     |
| Pharmaceuticals                   | 10.3            | 20.5      | 31.3      | 41.3      | 9.8             | -         | -         | -         | 20.5              | 40.7      |
| <i>R&amp;D to net sales ratio</i> | 15.3%           | 16.1%     | 16.5%     | 15.9%     | 14.7%           | -         | -         | -         | 15.8%             | 15.7%     |
| Bio-Chemicals                     | 0.7             | 1.5       | 2.3       | 3.4       | 0.7             | -         | -         | -         | 1.7               | 3.3       |

#### (2) Capital Expenditure (Tangible fixed assets)

Billions of yen, rounded down

|                     | FY 2012 results |           |           |           | FY 2013 results |           |           |           | FY 2013 forecasts |           |
|---------------------|-----------------|-----------|-----------|-----------|-----------------|-----------|-----------|-----------|-------------------|-----------|
|                     | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Jun         | Jan - Dec |
| Capital expenditure | 4.1             | 7.9       | 14.7      | 19.7      | 5.3             | -         | -         | -         | 7.4               | 19.2      |
| Pharmaceuticals     | 2.1             | 4.0       | 7.3       | 10.3      | 1.8             | -         | -         | -         | 3.7               | 9.5       |
| Bio-Chemicals       | 1.9             | 3.9       | 7.4       | 9.4       | 3.5             | -         | -         | -         | 3.7               | 9.7       |

#### (3) Depreciation and amortization Expenses (Tangible and intangible fixed assets)

Billions of yen, rounded down

|  | FY 2012 results |           |           |           | FY 2013 results |           |           |           | FY 2013 forecasts |           |
|--|-----------------|-----------|-----------|-----------|-----------------|-----------|-----------|-----------|-------------------|-----------|
|  | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Jun         | Jan - Dec |
| Depreciation and amortization expenses         | 4.6             | 9.6       | 14.5      | 20.9      | 4.8             | -         | -         | -         | 9.9               | 21.2      |
| <i>Amortization of intangible fixed assets</i> | 1.0             | 2.4       | 3.5       | 5.4       | 1.5             | -         | -         | -         | 2.9               | 6.1       |
| Pharmaceuticals                                | 3.1             | 6.6       | 10.1      | 14.5      | 3.3             | -         | -         | -         | 6.7               | 14.6      |
| <i>Amortization of intangible fixed assets</i> | 1.0             | 2.4       | 3.5       | 5.4       | 1.5             | -         | -         | -         | 2.8               | 6.1       |
| Bio-Chemicals                                  | 1.5             | 2.9       | 4.4       | 6.2       | 1.5             | -         | -         | -         | 3.1               | 6.6       |

\*Amortization expenses do not include goodwill amortization expenses

#### (4) Goodwill Amortization Expenses

Billions of yen, rounded down

|   | FY 2012 results |           |           |           | FY 2013 results |           |           |           | FY 2013 forecasts |           |
|---|-----------------|-----------|-----------|-----------|-----------------|-----------|-----------|-----------|-------------------|-----------|
|   | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Jun         | Jan - Dec |
| Goodwill amortization expenses                            | 3.0             | 6.0       | 9.1       | 12.0      | 2.8             | -         | -         | -         | 5.7               | 11.4      |
| <i>Reverse acquisition goodwill amortization expenses</i> | 2.3             | 4.6       | 6.9       | 9.2       | 2.3             | -         | -         | -         | 4.6               | 9.2       |
| Pharmaceuticals   | 2.9             | 5.7       | 8.6       | 11.4      | 2.7             | -         | -         | -         | 5.4               | 10.8      |
| <i>Reverse acquisition goodwill amortization</i>          | 2.1             | 4.3       | 6.4       | 8.6       | 2.1             | -         | -         | -         | 4.3               | 8.6       |
| Bio-Chemicals   | 0.1             | 0.3       | 0.4       | 0.6       | 0.1             | -         | -         | -         | 0.3               | 0.6       |
| <i>Reverse acquisition goodwill amortization</i>          | 0.1             | 0.3       | 0.4       | 0.6       | 0.1             | -         | -         | -         | 0.3               | 0.6       |

\*\*Reverse acquisition goodwill amortization expenses\* refers to amortization of goodwill arising on the reverse acquisition in April 2008 (Kirin Pharma share transfer).

**II. Consolidated Subsidiaries and Affiliates**

(As of March 31, 2013)

| Segment                                      | Type                    | Region   | Company name                         | Percentage owned (direct and indirect)                          | Principal business  |
|--|-------------------------|--|--------------------------------------|---|---|
| Pharmaceuticals                              | Consolidated subsidiary | Japan  | Kyowa Medex Co., Ltd.                | 100.0%  | Manufacture and sale of diagnostic reagents   |
|  |                         |  | Kyowa Medical Promotion Co., Ltd.    | 100.0%  | Promotion and sales of pharmaceuticals  |
|  |                         |  | Chiyoda Kaihatsu Co., Ltd. *1        | 100.0%  | Distribution, contracting, wholesale and retail and insurance agency business                 |
|  |                         | The Americas                                     | Kyowa Hakko Kirin America, Inc.      | 100.0%  | Holding company for administration and management of subsidiaries (US)                        |
|  |                         |  | BioWa, Inc.                          | 100.0%  | Out-licensing of anti-body technology (US)  |
|  |                         |  | Kyowa Hakko Kirin Pharma, Inc.       | 100.0%  | Development of outsourced pharmaceutical products (US)  |
|  |                         |  | Kyowa Hakko Kirin California, Inc.   | 100.0%  | Generate new candidate substances and develop pharmaceuticals (US)                            |
|  |                         |  | Hematech, Inc.                       | 100.0%  | (Company to be discontinued)  |
|  |                         |  | ProStrakan Inc.                      | 100.0%  | Sales of pharmaceuticals (US)   |
|  |                         |  | Europe                               | ProStrakan Group plc  | 100.0%  |
|  |                         | Strakan International S.a r.l.                   |                                      | 100.0%  | Sales, licensing-in and licensing-out of pharmaceuticals (UK)                                 |
|  |                         | Strakan Pharmaceuticals Limited                  |                                      | 100.0%  | Development of pharmaceuticals (UK)   |
|  |                         | ProStrakan Limited                               |                                      | 100.0%  | Sales of pharmaceuticals (UK)   |
|  |                         | ProStrakan Pharma S.A.S                          |                                      | 100.0%  | Sales of pharmaceuticals (France)   |
|  |                         | ProStrakan Farmaceutica SLU                      |                                      | 100.0%  | Sales of pharmaceuticals (Spain)  |
|  |                         | ProStrakan Pharma GmbH                           |                                      | 100.0%  | Sales of pharmaceuticals (Germany)  |
|  |                         | ProStrakan Holdings B.V.                         |                                      | 100.0%  | Holding company for special companies (Netherlands)   |
|  |                         | ProStrakan Pharma B.V.                           |                                      | 100.0%  | Sales of pharmaceuticals (Netherlands)  |
|  |                         | ProStrakan S.r.l.                                |                                      | 100.0%  | Sales of pharmaceuticals (Italy)  |
|  | ProStrakan AB           | 100.0%   | Sales of pharmaceuticals (Sweden)    |   |   |
|  | Asia                    | Kyowa Hakko Kirin China Pharmaceutical Co., Ltd. | 100.0%                               | Manufacture and sale of pharmaceuticals (China)                 |   |
|  |                         | Kyowa Hakko Kirin Korea Co., Ltd.                | 100.0%                               | Sales of pharmaceuticals (Korea)                                |   |
| Kyowa Hakko Kirin (Taiwan) Co., Ltd.         |                         | 100.0%   | Sales of pharmaceuticals (Taiwan)    |   |   |
| Kyowa Hakko Kirin (Hong Kong) Co., Ltd.      |                         | 100.0%   | Sales of pharmaceuticals (Hong Kong) |   |   |
| Kyowa Hakko Kirin (Singapore) Pte. Ltd.      |                         | 100.0%   | Sales of pharmaceuticals (Singapore) |   |   |
| Affiliate accounted for by the equity method | Japan                   | FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.         | 50.0%                                | Development, manufacture and sale of biosimilar pharmaceuticals |   |
|  |                         | Japan Synthetic Alcohol Co., Ltd. *1 □           | 33.3%                                | Manufacture and sale of industrial alcohol                      |   |
| Bio-Chemicals                                | Consolidated subsidiary | Japan  | Kyowa Hakko Bio Co., Ltd.            | 100.0%  | Manufacture and sale of pharmaceutical and industrial raw materials, and health care products |
|  |                         |  | Daiichi Fine Chemical Co., Ltd.      | 100.0%  | Manufacture and sale of active pharmaceutical ingredients and pharmaceutical intermediates    |
|  |                         |  | Kyowa Engineering Co., Ltd.          | 100.0%  | Design and installation of plant facilities and equipment                                     |
|  |                         | The Americas                                     | BioKyowa Inc.                        | 100.0%  | Manufacture and sale of amino acids (US)  |
|  |                         |  | Kyowa Hakko U.S.A., Inc.             | 100.0%  | Sale and import/export of fine chemicals including amino acids (US)                           |
|  |                         |  | Kyowa Hakko Bio U.S. Holdings, Inc.  | 100.0%  | Holding company for administration and management of US special companies (US)                |
|  |                         | Europe   | Kyowa Hakko Europe GmbH              | 100.0%  | Sale and import/export of fine chemicals including amino acids (Germany)                      |
|  |                         |  | Kyowa Hakko Bio Italia S.r.l.        | 100.0%  | Sale and import/export of fine chemicals including amino acids (Italy)                        |
|  |                         | Asia   | Shanghai Kyowa Amino Acid Co., Ltd.  | 70.0%   | Manufacture and sale of amino acids (China)   |
|  |                         |  | Thai Kyowa Biotechnologies Co., Ltd. | 100.0%  | Manufacture and sale of amino acids (Thailand)  |
|  |                         |  | Kyowa Hakko (H.K.) Co., Ltd.         | 100.0%  | Sale and import/export of fine chemicals including amino acids (Hong Kong)                    |
|  |                         |  | Kyowa Hakko Bio Singapore Pte. Ltd.  | 100.0%  | Sale and import/export of fine chemicals including amino acids (Singapore)                    |

Changes in scope of consolidation resulting in changes in subsidiaries (2013.1.1~2013.3.31)

New: None

Exclusions: One: Kyowa Hakko Wellness (see Note 2)

Notes: 1. As a result of the discontinuation of the 'Other' segment from 2013 Chiyoda Kaihatsu Co., and Japan Synthetic Alcohol Co., Ltd. have been included in the Pharmaceuticals segment.

2. Kyowa Wellness no longer exists following its merger with Kyowa Hakko Bio on January 1, 2013.

III. Kyowa Hako Kirin Sales of main products

Accumulative

Billions of yen, rounded down

|  | FY 2012 results |           |           |           | FY 2013 results |               |          |           |          |           |          |           | FY 2013 forecasts |           |          |           |          |
|--|-----------------|-----------|-----------|-----------|-----------------|---------------|----------|-----------|----------|-----------|----------|-----------|-------------------|-----------|----------|-----------|----------|
|  | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Change Amount | Change % | Jan - Jun | Change % | Jan - Sep | Change % | Jan - Dec | Change %          | Jan - Jun | Change % | Jan - Dec | Change % |
| <b>Kyowa Hako Kirin total</b>  | 57.8            | 107.8     | 159.4     | 218.1     | 56.4            | (1.4)         | 98%      | -         | -        | -         | -        | -         | -                 | 108.7     | 101%     | 212.3     | 97%      |
| <b>Indication / Product name</b>                                       |                 |           |           |           |                 |               |          |           |          |           |          |           |                   |           |          |           |          |
| <i>ESA formulation</i><br><b>Nesp</b>                                  | 13.8            | 26.8      | 41.0      | 58.1      | 10.6            | (3.1)         | 77%      | -         | -        | -         | -        | -         | -                 | 27.7      | 103%     | 57.8      | 99%      |
| <i>ESA formulation</i><br><b>Espo</b>                                  | 0.9             | 1.9       | 2.9       | 3.9       | 0.7             | (0.2)         | 71%      | -         | -        | -         | -        | -         | -                 | 1.7       | 90%      | 3.5       | 90%      |
| <b>Nesp/Espo</b>   | 14.8            | 28.8      | 43.9      | 62.0      | 11.3            | (3.4)         | 77%      | -         | -        | -         | -        | -         | -                 | 29.5      | 102%     | 61.3      | 99%      |
| <i>Secondary hyperparathyroidism</i><br><b>Regpara</b>                 | 2.8             | 6.2       | 9.5       | 13.4      | 3.0             | 0.2           | 110%     | -         | -        | -         | -        | -         | -                 | 6.7       | 109%     | 14.1      | 105%     |
| <i>Secondary hyperparathyroidism</i><br><b>Rocaltrol</b>               | 0.7             | 1.6       | 2.5       | 3.6       | 0.7             | 0.0           | 104%     | -         | -        | -         | -        | -         | -                 | 1.8       | 108%     | 3.6       | 101%     |
| <i>Antiallergenic</i><br><b>Allelock</b>                               | 9.9             | 16.1      | 21.8      | 29.9      | 10.7            | 0.8           | 109%     | -         | -        | -         | -        | -         | -                 | 16.2      | 100%     | 27.8      | 93%      |
| <i>Antiallergenic</i><br><b>Cellect</b>                                | 0.5             | 1.0       | 1.4       | 1.9       | 0.4             | (0.0)         | 89%      | -         | -        | -         | -        | -         | -                 | 1.0       | 97%      | 1.8       | 96%      |
| <i>Antiallergic eyedrops</i><br><b>Patanol</b>                         | 5.4             | 6.9       | 8.5       | 10.2      | 9.4             | 3.9           | 172%     | -         | -        | -         | -        | -         | -                 | 8.1       | 117%     | 11.4      | 111%     |
| <i>G-CSF</i><br><b>Gran</b>  | 2.9             | 6.4       | 9.8       | 13.5      | 2.5             | (0.3)         | 87%      | -         | -        | -         | -        | -         | -                 | 6.0       | 94%      | 12.6      | 93%      |
| <i>Cancer pain</i><br><b>Fentos</b>                                    | 0.8             | 2.0       | 3.2       | 4.6       | 1.0             | 0.1           | 118%     | -         | -        | -         | -        | -         | -                 | 2.4       | 120%     | 5.5       | 119%     |
| <i>Anticancer</i><br><b>5-FU</b>                                       | 0.6             | 1.4       | 2.1       | 2.8       | 0.6             | (0.0)         | 90%      | -         | -        | -         | -        | -         | -                 | 1.4       | 100%     | 2.8       | 99%      |
| <i>Anticancer</i><br><b>Navelbine</b>                                  | 0.3             | 0.6       | 0.9       | 1.3       | 0.2             | (0.0)         | 79%      | -         | -        | -         | -        | -         | -                 | 0.6       | 90%      | 1.1       | 88%      |
| <i>Chronic idiopathic thrombocytopenic purpura</i><br><b>Romiplate</b> | 0.3             | 0.7       | 1.2       | 1.7       | 0.4             | 0.1           | 138%     | -         | -        | -         | -        | -         | -                 | 0.8       | 116%     | 1.8       | 102%     |
| <i>Cardiovascular</i><br><b>Coniel</b>                                 | 4.2             | 8.5       | 12.5      | 17.1      | 3.5             | (0.6)         | 84%      | -         | -        | -         | -        | -         | -                 | 7.6       | 90%      | 15.4      | 90%      |
| <i>Cardiovascular (Hypertension)</i><br><b>Coversyl</b>                | 0.8             | 1.7       | 2.5       | 3.5       | 0.7             | (0.0)         | 95%      | -         | -        | -         | -        | -         | -                 | 1.5       | 89%      | 3.1       | 88%      |
| <i>Cardiovascular</i><br><b>Inovan / Pre Dopa *1</b>                   | 0.6             | 1.1       | 1.7       | 2.4       | 0.4             | (0.1)         | 76%      | -         | -        | -         | -        | -         | -                 | 0.9       | 80%      | 1.8       | 79%      |
| <i>Antiepileptic</i><br><b>Depakene</b>                                | 2.4             | 5.2       | 7.8       | 10.7      | 2.3             | (0.1)         | 95%      | -         | -        | -         | -        | -         | -                 | 5.1       | 99%      | 10.5      | 99%      |
| <i>Parkinson's disease</i><br><b>Permax</b>                            | 0.3             | 0.8       | 1.2       | 1.7       | 0.3             | (0.0)         | 76%      | -         | -        | -         | -        | -         | -                 | 0.8       | 100%     | 1.7       | 103%     |
| <i>Gastrointestinal</i><br><b>Nauzelin</b>                             | 1.1             | 2.2       | 3.2       | 4.9       | 1.0             | (0.0)         | 95%      | -         | -        | -         | -        | -         | -                 | 2.4       | 107%     | 4.9       | 100%     |
| <i>Inflammatory bowel disease</i><br><b>Asacol</b>                     | 0.8             | 1.8       | 2.8       | 4.1       | 1.0             | 0.2           | 135%     | -         | -        | -         | -        | -         | -                 | 2.3       | 127%     | 4.8       | 117%     |
| <b>Exports and Technology Out-Licensing</b>                            |                 |           |           |           |                 |               |          |           |          |           |          |           |                   |           |          |           |          |
| <b>Exports</b>   | 3.1             | 5.7       | 7.5       | 9.4       | 3.2             | 0.0           | 103%     | -         | -        | -         | -        | -         | -                 | 4.6       | 82%      | 9.2       | 98%      |
| <b>Technology Out-Licensing</b>  | 8.1             | 12.0      | 18.9      | 24.4      | 4.8             | (3.2)         | 60%      | -         | -        | -         | -        | -         | -                 | 11.3      | 95%      | 18.8      | 77%      |

\*1 Sales of Pre Dopa terminated on February 28, 2013. As a result Inovan/ Pre Dopa from March 2013 are figure for Inovan only.



III. Kyowa Hakko Kirin Sales of main products

Quarterly

Billions of yen, rounded down

|   | FY 2012 results |           |           |           | FY 2013 results |               |          |           |          |           |          |           | FY 2013 forecasts |           |          |           |          |
|---|-----------------|-----------|-----------|-----------|-----------------|---------------|----------|-----------|----------|-----------|----------|-----------|-------------------|-----------|----------|-----------|----------|
|   | Jan - Mar       | Apr - Jun | Jul - Sep | Oct - Dec | Jan - Mar       | Change Amount | Change % | Apr - Jun | Change % | Jul - Sep | Change % | Oct - Dec | Change %          | Jan - Jun | Change % | Jul - Dec | Change % |
| <b>Kyowa Hakko Kirin total</b>                                  | 57.8            | 49.9      | 51.6      | 58.6      | 56.4            | (1.4)         | 98%      | -         | -        | -         | -        | -         | -                 | 108.7     | 101%     | 103.5     | 94%      |
| <b>Indication / Product name</b>                                |                 |           |           |           |                 |               |          |           |          |           |          |           |                   |           |          |           |          |
| ESA formulation<br><b>Nesp</b>                                  | 13.8            | 12.9      | 14.2      | 17.0      | 10.6            | (3.1)         | 77%      | -         | -        | -         | -        | -         | -                 | 27.7      | 103%     | 30.0      | 96%      |
| ESA formulation<br><b>Espo</b>                                  | 0.9             | 0.9       | 0.9       | 0.9       | 0.7             | (0.2)         | 71%      | -         | -        | -         | -        | -         | -                 | 1.7       | 90%      | 1.7       | 89%      |
| <b>Nesp/Espo</b>  | 14.8            | 13.9      | 15.1      | 18.0      | 11.3            | (3.4)         | 77%      | -         | -        | -         | -        | -         | -                 | 29.5      | 102%     | 31.8      | 96%      |
| Secondary hyperparathyroidism<br><b>Regpara</b>                 | 2.8             | 3.4       | 3.3       | 3.8       | 3.0             | 0.2           | 110%     | -         | -        | -         | -        | -         | -                 | 6.7       | 109%     | 7.3       | 102%     |
| Secondary hyperparathyroidism<br><b>Rocalrol</b>                | 0.7             | 0.9       | 0.9       | 1.0       | 0.7             | 0.0           | 104%     | -         | -        | -         | -        | -         | -                 | 1.8       | 108%     | 1.8       | 94%      |
| Antiallergenic<br><b>Allelock</b>                               | 9.9             | 6.2       | 5.7       | 8.0       | 10.7            | 0.8           | 109%     | -         | -        | -         | -        | -         | -                 | 16.2      | 100%     | 11.5      | 84%      |
| Antiallergenic<br><b>Cellect</b>                                | 0.5             | 0.4       | 0.3       | 0.4       | 0.4             | (0.0)         | 89%      | -         | -        | -         | -        | -         | -                 | 1.0       | 97%      | 0.8       | 95%      |
| Antiallergic eyedrops<br><b>Patanol</b>                         | 5.4             | 1.4       | 1.6       | 1.7       | 9.4             | 3.9           | 172%     | -         | -        | -         | -        | -         | -                 | 8.1       | 117%     | 3.3       | 100%     |
| G-CSF<br><b>Gran</b>  | 2.9             | 3.4       | 3.4       | 3.7       | 2.5             | (0.3)         | 87%      | -         | -        | -         | -        | -         | -                 | 6.0       | 94%      | 6.5       | 92%      |
| Cancer pain<br><b>Fentos</b>                                    | 0.8             | 1.1       | 1.1       | 1.4       | 1.0             | 0.1           | 118%     | -         | -        | -         | -        | -         | -                 | 2.4       | 120%     | 3.0       | 118%     |
| Anticancer<br><b>5-FU</b>                                       | 0.6             | 0.7       | 0.6       | 0.7       | 0.6             | (0.0)         | 90%      | -         | -        | -         | -        | -         | -                 | 1.4       | 100%     | 1.4       | 98%      |
| Anticancer<br><b>Navelbine</b>                                  | 0.3             | 0.3       | 0.3       | 0.3       | 0.2             | (0.0)         | 79%      | -         | -        | -         | -        | -         | -                 | 0.6       | 90%      | 0.5       | 86%      |
| Chronic idiopathic thrombocytopenic purpura<br><b>Romiplate</b> | 0.3             | 0.4       | 0.4       | 0.5       | 0.4             | 0.1           | 138%     | -         | -        | -         | -        | -         | -                 | 0.8       | 116%     | 0.9       | 92%      |
| Cardiovascular<br><b>Coniel</b>                                 | 4.2             | 4.3       | 4.0       | 4.5       | 3.5             | (0.6)         | 84%      | -         | -        | -         | -        | -         | -                 | 7.6       | 90%      | 7.7       | 91%      |
| Cardiovascular (Hypertension)<br><b>Coversyl</b>                | 0.8             | 0.9       | 0.8       | 0.9       | 0.7             | (0.0)         | 95%      | -         | -        | -         | -        | -         | -                 | 1.5       | 89%      | 1.5       | 87%      |
| Cardiovascular<br><b>Inovan / Pre Dopa *1</b>                   | 0.6             | 0.5       | 0.5       | 0.6       | 0.4             | (0.1)         | 76%      | -         | -        | -         | -        | -         | -                 | 0.9       | 80%      | 0.9       | 77%      |
| Antiepileptic<br><b>Depakene</b>                                | 2.4             | 2.7       | 2.5       | 2.9       | 2.3             | (0.1)         | 95%      | -         | -        | -         | -        | -         | -                 | 5.1       | 99%      | 5.4       | 98%      |
| Parkinson's disease<br><b>Permax</b>                            | 0.3             | 0.4       | 0.4       | 0.4       | 0.3             | (0.0)         | 76%      | -         | -        | -         | -        | -         | -                 | 0.8       | 100%     | 0.8       | 106%     |
| Gastrointestinal<br><b>Nauzelin</b>                             | 1.1             | 1.1       | 0.9       | 1.7       | 1.0             | (0.0)         | 95%      | -         | -        | -         | -        | -         | -                 | 2.4       | 107%     | 2.5       | 94%      |
| Inflammatory bowel disease<br><b>Asacol</b>                     | 0.8             | 1.0       | 1.0       | 1.2       | 1.0             | 0.2           | 135%     | -         | -        | -         | -        | -         | -                 | 2.3       | 127%     | 2.4       | 109%     |
| <b>Exports and Technology Out-Licensing</b>                     |                 |           |           |           |                 |               |          |           |          |           |          |           |                   |           |          |           |          |
| <b>Exports</b>  | 3.1             | 2.5       | 1.8       | 1.8       | 3.2             | 0.0           | 103%     | -         | -        | -         | -        | -         | -                 | 4.6       | 82%      | 4.5       | 123%     |
| <b>Technology Out-Licensing</b>                                 | 8.1             | 3.8       | 6.9       | 5.5       | 4.8             | (3.2)         | 60%      | -         | -        | -         | -        | -         | -                 | 11.3      | 95%      | 7.4       | 60%      |

\*1 Sales of Pre Dopa terminated on February 28, 2013. As a result Inovan/ Pre Dopa from March 2013 are figure for Inovan only.

#### IV. Segment information and main subsidiaries operating profit or loss

##### 1. Pharmaceuticals segment

###### (1) Pharmaceuticals segment total

Billions of yen, rounded down

|                  | FY 2012 results |           |           |           | FY 2013 results |               |          |           | FY 2013 forecasts |           |          |           |          |           |          |           |          |
|------------------|-----------------|-----------|-----------|-----------|-----------------|---------------|----------|-----------|-------------------|-----------|----------|-----------|----------|-----------|----------|-----------|----------|
|                  | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Change Amount | Change % | Jan - Jun | Change %          | Jan - Sep | Change % | Jan - Dec | Change % | Jan - Jun | Change % | Jan - Dec | Change % |
| Net sales        | 67.2            | 127.5     | 189.4     | 259.3     | 67.4            | 0.2           | 100%     | -         | -                 | -         | -        | -         | -        | 130.0     | 102%     | 260.0     | 100%     |
| Japan sales      | 56.9            | 105.6     | 157.2     | 215.9     | 55.2            | (1.6)         | 97%      | -         | -                 | -         | -        | -         | -        | 109.0     | 103%     | 215.0     | 100%     |
| Overseas sales   | 10.3            | 21.9      | 32.2      | 43.3      | 12.1            | 1.8           | 118%     | -         | -                 | -         | -        | -         | -        | 21.0      | 96%      | 45.0      | 104%     |
| America          | 2.6             | 6.4       | 9.8       | 14.2      | 3.3             | 0.6           | 126%     | -         | -                 | -         | -        | -         | -        | 6.0       | 93%      | 14.0      | 98%      |
| Europe           | 5.2             | 10.3      | 14.6      | 18.9      | 5.8             | 0.5           | 111%     | -         | -                 | -         | -        | -         | -        | 10.0      | 97%      | 21.0      | 111%     |
| Asia and others  | 2.4             | 5.1       | 7.7       | 10.1      | 2.9             | 0.5           | 122%     | -         | -                 | -         | -        | -         | -        | 5.0       | 98%      | 10.0      | 98%      |
| Operating income | 16.7            | 23.5      | 35.1      | 50.7      | 13.0            | (3.6)         | 78%      | -         | -                 | -         | -        | -         | -        | 25.6      | 109%     | 49.2      | 97%      |

###### (2) ProStrakan (GBP)

Millions of GBP, rounded down

|  | FY 2012 results |           |           |           | FY 2013 results |               |          |           | FY 2013 forecasts |           |          |           |          |           |          |           |          |
|--|-----------------|-----------|-----------|-----------|-----------------|---------------|----------|-----------|-------------------|-----------|----------|-----------|----------|-----------|----------|-----------|----------|
|  | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Change Amount | Change % | Jan - Jun | Change %          | Jan - Sep | Change % | Jan - Dec | Change % | Jan - Jun | Change % | Jan - Dec | Change % |
| Net sales  | 29.3            | 61.4      | 92.6      | 129.4     | 35.7            | 6.4           | 122%     | -         | -                 | -         | -        | -         | -        | 74.0      | 121%     | 154.3     | 119%     |
| Chemotherapy-induced nausea and vomiting drug<br><b>Sancuso</b>  | 2.8             | 5.9       | 9.5       | 12.3      | 3.0             | 0.1           | 107%     | -         | -                 | -         | -        | -         | -        | 9.0       | 150%     | 19.8      | 161%     |
| Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain<br><b>Abstral</b> | 7.2             | 16.3      | 24.5      | 33.9      | 10.5            | 3.2           | 144%     | -         | -                 | -         | -        | -         | -        | 20.5      | 126%     | 42.5      | 125%     |
| Replacement therapy with testosterone for male hypogonadism<br><b>Tostran</b>                                    | 1.6             | 2.9       | 4.3       | 7.5       | 1.8             | 0.2           | 113%     | -         | -                 | -         | -        | -         | -        | 5.0       | 175%     | 11.0      | 147%     |
| Relief of pain associated with chronic anal fissures<br><b>Rectogesic</b>  | 2.4             | 4.8       | 7.2       | 10.1      | 2.9             | 0.5           | 121%     | -         | -                 | -         | -        | -         | -        | 6.1       | 128%     | 12.9      | 128%     |
| Osteoporosis drug<br><b>Adcal-D3</b>   | 5.9             | 12.5      | 19.0      | 26.3      | 6.7             | 0.7           | 113%     | -         | -                 | -         | -        | -         | -        | 12.2      | 98%      | 26.7      | 101%     |
| Others   | 6.0             | 12.0      | 18.1      | 25.8      | 7.0             | 1.0           | 117%     | -         | -                 | -         | -        | -         | -        | 13.9      | 115%     | 27.1      | 105%     |
| Product net sales (subtotal)   | 26.3            | 54.7      | 82.8      | 116.2     | 32.2            | 5.9           | 123%     | -         | -                 | -         | -        | -         | -        | 67.0      | 122%     | 140.3     | 121%     |
| Technology Out-Licensing and others  | 2.9             | 6.6       | 9.8       | 13.1      | 3.4             | 0.4           | 116%     | -         | -                 | -         | -        | -         | -        | 7.2       | 109%     | 14.3      | 109%     |
| Gross profit   | 19.5            | 40.9      | 64.4      | 91.9      | 27.4            | 7.9           | 140%     | -         | -                 | -         | -        | -         | -        | 56.9      | 139%     | 118.1     | 129%     |
| Selling, general and administrative expenses *1  | 18.5            | 38.2      | 55.6      | 72.4      | 19.3            | 0.8           | 105%     | -         | -                 | -         | -        | -         | -        | 43.2      | 113%     | 82.3      | 114%     |
| EBIDTA *2  | 1.0             | 2.6       | 8.7       | 19.5      | 8.0             | 7.0           | 785%     | -         | -                 | -         | -        | -         | -        | 13.6      | 519%     | 35.8      | 184%     |
| Goodwill amortization *1   | 9.8             | 19.1      | 29.4      | 39.4      | 9.9             | 0.1           | 101%     | -         | -                 | -         | -        | -         | -        | 19.9      | 104%     | 39.9      | 101%     |
| Operating income   | (8.8)           | (16.5)    | (20.7)    | (19.9)    | (1.8)           | 6.9           | -        | -         | -                 | -         | -        | -         | -        | (6.3)     | 38%      | (4.1)     | 21%      |

\*1 Amortization of goodwill is not included in Selling, general and administrative expenses.

Goodwill amortization= Depreciation + Goodwill amortization

\*2 EBITDA=Operating income + depreciation + goodwill amortization.

\*3 Geographical breakdown of sales is as follows:

| UK    | Europe (excluding UK) | USA   | Other |
|-------|-----------------------|-------|-------|
| 31.4% | 43.6%                 | 22.9% | 2.2%  |

###### (3) Kyowa Medex

Billions of yen, rounded down

|                                   | FY 2012 results |           |           |           | FY 2013 results |               |          |           | FY 2013 forecasts |           |          |           |          |           |          |           |          |
|-----------------------------------|-----------------|-----------|-----------|-----------|-----------------|---------------|----------|-----------|-------------------|-----------|----------|-----------|----------|-----------|----------|-----------|----------|
|                                   | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Change Amount | Change % | Jan - Jun | Change %          | Jan - Sep | Change % | Jan - Dec | Change % | Jan - Jun | Change % | Jan - Dec | Change % |
| Net sales                         | 2.7             | 5.8       | 8.8       | 11.9      | 2.5             | (0.2)         | 92%      | -         | -                 | -         | -        | -         | -        | 5.7       | 99%      | 12.0      | 101%     |
| Japan sales                       | 2.0             | 4.6       | 7.1       | 9.7       | 2.0             | (0.0)         | 99%      | -         | -                 | -         | -        | -         | -        | 4.7       | 101%     | 10.0      | 103%     |
| Biochemical Diagnostic Reagents   | 0.8             | 1.8       | 2.9       | 4.0       | 0.8             | (0.0)         | 99%      | -         | -                 | -         | -        | -         | -        | 1.9       | 104%     | 4.1       | 104%     |
| Immunological Diagnostic Reagents | 1.0             | 2.2       | 3.4       | 4.7       | 1.0             | 0.0           | 101%     | -         | -                 | -         | -        | -         | -        | 2.2       | 99%      | 4.7       | 100%     |
| Other                             | 0.2             | 0.5       | 0.7       | 0.9       | 0.2             | (0.0)         | 95%      | -         | -                 | -         | -        | -         | -        | 0.5       | 103%     | 1.1       | 117%     |
| Exports                           | 0.6             | 1.1       | 1.6       | 2.2       | 0.4             | (0.1)         | 71%      | -         | -                 | -         | -        | -         | -        | 1.0       | 90%      | 2.0       | 92%      |
| Operating income                  | 0.2             | 0.5       | 0.8       | 1.2       | 0.0             | (0.2)         | 20%      | -         | -                 | -         | -        | -         | -        | 0.4       | 72%      | 1.0       | 85%      |

#### IV. Segment information and main subsidiaries operating profit or loss

##### 2. Bio-Chemicals segment

###### (1) Bio-Chemicals segment total

Billions of yen, rounded down

|                  | FY 2012 results |           |           |           | FY 2013 results |               |          |           | FY 2013 forecasts |           |          |           |          |           |          |           |          |
|------------------|-----------------|-----------|-----------|-----------|-----------------|---------------|----------|-----------|-------------------|-----------|----------|-----------|----------|-----------|----------|-----------|----------|
|                  | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Change Amount | Change % | Jan - Jun | Change %          | Jan - Sep | Change % | Jan - Dec | Change % | Jan - Jun | Change % | Jan - Dec | Change % |
| Net sales        | 20.5            | 40.0      | 57.4      | 76.9      | 19.9            | (0.5)         | 97%      | -         | -                 | -         | -        | -         | -        | 40.0      | 100%     | 81.0      | 105%     |
| Japan sales      | 12.7            | 24.5      | 35.0      | 47.7      | 11.5            | (1.1)         | 91%      | -         | -                 | -         | -        | -         | -        | 22.9      | 93%      | 47.3      | 99%      |
| Overseas sales   | 7.8             | 15.4      | 22.4      | 29.2      | 8.4             | 0.5           | 107%     | -         | -                 | -         | -        | -         | -        | 17.1      | 110%     | 33.7      | 115%     |
| America          | 1.9             | 3.6       | 5.2       | 6.9       | 1.8             | (0.1)         | 95%      | -         | -                 | -         | -        | -         | -        | 4.0       | 110%     | 8.1       | 116%     |
| Europe           | 3.2             | 6.5       | 9.3       | 12.0      | 3.6             | 0.4           | 113%     | -         | -                 | -         | -        | -         | -        | 7.4       | 112%     | 14.1      | 117%     |
| Asia and others  | 2.7             | 5.2       | 7.8       | 10.2      | 2.9             | 0.2           | 109%     | -         | -                 | -         | -        | -         | -        | 5.7       | 109%     | 11.5      | 112%     |
| Operating income | 1.3             | 2.0       | 2.2       | 2.1       | 1.4             | 0.1           | 114%     | -         | -                 | -         | -        | -         | -        | 3.4       | 167%     | 5.8       | 273%     |

###### (2) Kyowa Hakkio Bio Co., Ltd.

Billions of yen, rounded down

|   | FY 2012 results |           |           |           | FY 2013 results |               |          |           | FY 2013 forecasts |           |          |           |          |           |          |           |          |
|---|-----------------|-----------|-----------|-----------|-----------------|---------------|----------|-----------|-------------------|-----------|----------|-----------|----------|-----------|----------|-----------|----------|
|   | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Change Amount | Change % | Jan - Jun | Change %          | Jan - Sep | Change % | Jan - Dec | Change % | Jan - Jun | Change % | Jan - Dec | Change % |
| Net sales                               | 12.9            | 25.9      | 38.0      | 51.2      | 13.8            | 0.9           | 107%     | -         | -                 | -         | -        | -         | -        | 28.7      | 111%     | 57.2      | 112%     |
| Japan sales                             | 8.1             | 16.4      | 24.2      | 32.7      | 8.8             | 0.6           | 108%     | -         | -                 | -         | -        | -         | -        | 17.9      | 109%     | 36.1      | 110%     |
| Pharmaceutical and industrial materials | 3.4             | 7.0       | 10.7      | 14.1      | 3.8             | 0.3           | 109%     | -         | -                 | -         | -        | -         | -        | 6.8       | 96%      | 13.6      | 96%      |
| Healthcare                              | 2.2             | 4.7       | 7.1       | 9.3       | 2.4             | 0.1           | 108%     | -         | -                 | -         | -        | -         | -        | 6.4       | 137%     | 13.1      | 140%     |
| Other                                   | 2.3             | 4.6       | 6.4       | 9.2       | 2.5             | 0.1           | 106%     | -         | -                 | -         | -        | -         | -        | 4.6       | 100%     | 9.4       | 102%     |
| Exports                                 | 4.7             | 9.4       | 13.7      | 18.5      | 4.9             | 0.2           | 105%     | -         | -                 | -         | -        | -         | -        | 10.7      | 113%     | 21.0      | 114%     |
| Operating income                        | 0.5             | 1.2       | 1.4       | 1.1       | 1.2             | 0.7           | 227%     | -         | -                 | -         | -        | -         | -        | 1.8       | 151%     | 3.6       | 316%     |

###### (3) Daiichi Fine Chemical Co., Ltd.

Billions of yen, rounded down

|                  | FY 2012 results |           |           |           | FY 2013 results |               |          |           | FY 2013 forecasts |           |          |           |          |           |          |           |          |
|------------------|-----------------|-----------|-----------|-----------|-----------------|---------------|----------|-----------|-------------------|-----------|----------|-----------|----------|-----------|----------|-----------|----------|
|                  | Jan - Mar       | Jan - Jun | Jan - Sep | Jan - Dec | Jan - Mar       | Change Amount | Change % | Jan - Jun | Change %          | Jan - Sep | Change % | Jan - Dec | Change % | Jan - Jun | Change % | Jan - Dec | Change % |
| Net sales        | 3.7             | 6.7       | 8.8       | 12.8      | 2.9             | (0.8)         | 77%      | -         | -                 | -         | -        | -         | -        | 5.8       | 86%      | 12.5      | 98%      |
| Operating income | 0.2             | (0.2)     | (0.6)     | (1.0)     | (0.0)           | (0.2)         | -        | -         | -                 | -         | -        | -         | -        | (0.1)     | -        | (0.3)     | -        |







R&D Pipeline

KYOWAKIRIN















antibody protein small molecule

Filed · Approved

As of April 17th 2013











| Area                         |   | Code Name<br>Generic Name<br>Formulation                | Mechanism of Action                                | Indication                                  | Stage   | In-House<br>or<br>Licensed                                    | Remarks   |
|------------------------------|---|---|--|---|---|---|---|
| Oncology                     |  | <b>KW-2246</b><br>Fentanyl citrate<br>Sublingual Tablet | $\mu$ -Opioid Receptor<br>Agonist                  | Cancer Pain                                 | Filed in JP                                   | Licensed from<br>Orexo  |   |
|                              |  | <b>Granisetron</b><br>Patch                             | 5HT <sub>3</sub> Serotonin<br>Receptor Antagonist  | Chemotherapy induced<br>Nausea and Vomiting | Approved in HK<br>March 2013<br>Filed in Asia | Licensed from<br>Solasia<br>Pharma<br>(ProStrakan)            | Asia: Singapore and Malaysia                      |
| Nephrology                   |  | <b>Cinacalcet</b><br>Hydrochloride<br>Oral              | Calcium Receptor<br>Agonist                        | Secondary<br>Hyperparathyroidism            | Filed in Asia                                 | Licensed from<br>NPS  | Asia: Philippine, Malaysia, Thailand<br>and China |
|                              |  | <b>KRN321</b><br>Darbepoetin Alfa<br>Injection          | Long-Acting<br>Erythropoiesis<br>Stimulating Agent | Pediatric Renal Anemia                      | Filed in JP                                   | Kirin-<br>Amgen   |   |
| Central<br>Nervous<br>System |  | <b>©KW-6002</b><br>Istradefylline<br>Oral               | Adenosine A <sub>2A</sub><br>Receptor Antagonist   | Parkinson's Disease                         | Filed in US<br>Approved in JP<br>March 2013   | In-House  |   |
|                              |  | <b>KW-6485</b><br>Topiramate<br>Oral                    | Antiepileptic Drug                                 | Pediatric Epilepsy                          | Filed in JP                                   | Licensed from<br>Janssen<br>Research &<br>Development,<br>LLC |   |

Phase II, Phase III

| Area  |   | Code Name<br>Generic Name<br>Formulation           | Mechanism of Action  | Indication  | Stage                           | In-House<br>or<br>Licensed           | Remarks  |
|---|---|--|--|---|---------------------------------|--------------------------------------|--|
| Oncology  |    | <b>KRN125</b><br>Pegfilgrastim<br>Injection        | Long-Acting<br>Granulocyte<br>Colony Stimulating<br>Factor                                   | Chemotherapy induced<br>Febrile Neutropenia   | Phase III<br>in JP              | Kirin-<br>Amgen                      |  |
|   |    | <b>©ARQ 197</b><br>Tivantinib<br>Oral              | c-Met Inhibitor  | Lung Cancer<br>(EGF-receptor mutated)   | Phase II<br>in JP               | Licensed<br>from<br>ArQule           |  |
|   |   |  |  | Gastric Cancer  | Phase II<br>in JP and KR        |                                      |  |
|   |  | <b>KW-0761</b><br>Mogamulizumab<br>Injection       | Anti-CCR4<br>Humanized Antibody  | Peripheral T/NK-cell<br>Lymphoma  | Phase II<br>in JP               | In-House                             | POTELLIGENT*   |
|   |   |  |  | Adult T-cell<br>Leukemia/Lymphoma,<br>Add-on Therapy (for<br>Untreated Patients)    | Phase II<br>in JP               |                                      |  |
|   |   |  |  | Peripheral T-cell<br>Lymphoma   | Phase II<br>in EU               |                                      |  |
|   |   |  |  | Adult T-cell<br>Leukemia/Lymphoma   | Phase II<br>in US and EU        |                                      |  |
|  | <b>KRN1493</b><br>Cinacalcet<br>Hydrochloride<br>Oral                               | Calcium Receptor<br>Agonist                        | Hypercalcemia with<br>Parathyroid Carcinoma or<br>Intractable Primary<br>Hyperparathyroidism | Phase III<br>in JP  | Licensed<br>from<br>NPS         |                                      |  |
|  | <b>©KW-2478</b><br>Injection  | HSP90 inhibitor                                    | Multiple Myeloma   | Phase I / II<br>in UK/US/PH   | In-House                        |                                      |  |
|  | <b>KRN321</b><br>Darbepoetin Alfa<br>Injection                                      | Long-Acting<br>Erythropoiesis<br>Stimulating Agent | Myelodysplastic Syndrome<br>related Anemia   | Phase II<br>in JP and KR  | Kirin-<br>Amgen                 |                                      |  |
| Nephrology  |  | <b>KRN321</b><br>Darbepoetin Alfa<br>Injection     | Long-Acting<br>Erythropoiesis<br>Stimulating Agent   | Renal Anemia (on Dialysis)  | Phase II in CN                  | Kirin-<br>Amgen                      |  |
|   |  | <b>©RTA 402</b><br>Bardoxolone Methyl<br>Oral      | Antioxidant<br>Inflammation Modulator  | CKD in patients with type<br>2 diabetes   | Phase II<br>in JP               | Licensed<br>from<br>Reata            |  |
| Immunology<br>/Allergy  |  | <b>©KHK4563</b><br>Benralizumab<br>Injection       | Anti-IL-5 Receptor<br>Humanized Antibody   | Asthma  | Phase II<br>in JP and KR        | In-House                             | Being Developed by MedImmune as<br>MEDI-563 Worldwide except in<br>Japan and other Asian Countries<br>POTELLIGENT* |
|   |  | <b>©ASKP 1240</b><br>Injection                     | Anti-CD40 Fully<br>Human Antibody  | Organ Transplant<br>Rejection   | Phase I in JP<br>Phase II in US | In-House                             | Jointly Developed with Astellas<br>KM mouse  |
|   |  | <b>Z-206</b><br>Mesalazine<br>Oral                 | pH Dependent<br>Controlled<br>Release Tablet   | Crohn's Disease   | Phase II<br>in JP               | Licensed<br>from<br>Zeria<br>Pharma. | Jointly Developed with Zeria Pharma  |
|   |  | <b>©KHK4827</b><br>Injection                       | Anti-IL-17 Receptor<br>Fully Human Antibody  | Psoriasis   | Phase III<br>in JP              | Kirin-<br>Amgen                      |  |
| Central<br>Nervous<br>System  |  | <b>©KHK6188</b><br>Oral                            | Cannabinoid CB2<br>Receptor Agonist  | Neuropathic Pain  | Phase II<br>in JP               | In-House                             |  |
| Other   |  | <b>©KW-3357</b><br>Antithrombin<br>Injection       | Recombinant Human<br>Antithrombin  | Disseminated<br>Intravascular Coagulation,<br>Congenital Antithrombin<br>Deficiency | Phase III in JP                 | In-House                             |  |
|   |   |  |  |   | Phase I in EU                   |                                      |  |

Updated since Jan 24th, 2013 (Area, Stage, Filed, Approved, Launched etc.)

© New Molecular Entity

| Phase I                |   |  |   |   |                              |  |   |
|------------------------|---|--|---|---|------------------------------|--|---|
| Area                   |   | Code Name<br>Generic Name<br>Formulation | Mechanism of Action                                       | Indication  | Stage                        | In-House<br>or<br>Licensed               | Remarks   |
| Oncology               |  | ⓄBIW-8962<br>Injection                   | Anti-GM2 Humanized<br>Antibody                            | Cancer  | Phase I / II a<br>in US      | In-House                                 | POTELLIGENT®                                    |
|                        |  | ⓄKRN951<br>Tivozanib<br>Oral             | VEGF Receptor<br>Inhibitor                                | Cancer  | Phase I<br>in JP             | In-House                                 | Filed in US by AVEO<br>as AV-951                |
|                        |  | ⓄCEP-37250/K<br>HK2804<br>Injection      | Anti-Tumor Specific<br>Glycoprotein<br>Humanized Antibody | Cancer  | Phase I<br>in US             | Licensed<br>from<br>Cephalon             | Jointly Developed with Cephalon<br>POTELLIGENT® |
|                        |  | ⓄKHK2898<br>Injection                    | Anti-CD98 Fully<br>Human Antibody                         | Cancer  | Phase I<br>in SG             | In-House                                 | POTELLIGENT®<br>KM mouse                        |
|                        |  | ⓄARQ 197<br>Tivantinib<br>Oral           | c-Met Inhibitor   | Hepatocellular Cancer   | Phase I<br>in JP             | Licensed<br>from<br>ArQule               |   |
| Nephrology             |  | ⓄKHK7580<br>Oral                         | Calcium Receptor<br>Agonist                               | Secondary<br>Hyperparathyroidism                              | Phase I<br>in JP             | Licensed<br>from<br>Mitsubishi<br>Tanabe |   |
| Immunology<br>/Allergy |  | KW-0761<br>Mogamulzumab<br>Injection     | Anti-CCR4<br>Humanized Antibody                           | Asthma  | Phase I<br>in JP             | In-House                                 | POTELLIGENT®                                    |
|                        |  | ⓄKHK4083<br>Injection                    | Immunomodulator   | Autoimmune diseases   | Phase I<br>in CA             | In-House                                 | POTELLIGENT®<br>KM mouse                        |
|                        |  | ⓄKHK4577<br>Oral                         | Anti-inflammatory<br>Agent                                | Inflammatory disease  | Phase I<br>in JP             | In-House                                 |   |
| Other                  |  | ⓄKRN23<br>Injection                      | Anti-FGF23 Fully<br>Human Antibody                        | X-linked<br>Hypophosphatemic<br>Rickets/Osteomalacia<br>(XLH) | Phase I / II<br>in US and CA | In-House                                 | KM mouse  |



Updated since Jan 24th, 2013 (Area, Stage, Filed, Approved, Launched etc.)

Ⓞ New Molecular Entity

Updated since Jan 24th, 2013 (Area, Stage, Filed, Approved, Launched etc.)

Filed - Approved




As of April 17th 2013

| Area                         |   | Code Name<br>Generic Name<br>Formulation | Mechanism of Action                   | Indication                                  | Stage                        | In-House<br>or<br>Licensed                         | Remarks |
|------------------------------|---|--|---------------------------------------|---|------------------------------|--|---------|
| Oncology                     |  | Granisetron<br>Patch                     | 5HT3 Serotonin<br>Receptor Antagonist | Chemotherapy induced<br>Nausea and Vomiting | Approved in HK<br>March 2013 | Licensed from<br>Solasia<br>Pharma<br>(ProStrakan) |         |
| Central<br>Nervous<br>System |  | ⓄKW-6002<br>Istradefylline<br>Oral       | Adenosine A2A<br>Receptor Antagonist  | Parkinson's Disease                         | Approved in JP<br>March 2013 | In-House   |         |

Phase II, Phase III

| Area                   |   | Code Name<br>Generic Name<br>Formulation | Mechanism of Action                         | Indication | Stage              | In-House<br>or<br>Licensed | Remarks |
|------------------------|---|--|---|------------|--------------------|----------------------------|---------|
| Immunology<br>/Allergy |  | ⓄKHK4827<br>Injection                    | Anti-IL-17 Receptor<br>Fully Human Antibody | Psoriasis  | Phase III<br>in JP | Kirin-<br>Amgen            |         |

Discontinuation

| Area     |   | Code Name<br>Generic Name<br>Formulation | Mechanism of Action                | Indication | Stage                 | In-House<br>or<br>Licensed | Reason  |
|----------|---|--|------------------------------------|------------|-----------------------|----------------------------|---|
| Oncology |  | ⓄKW-2450<br>Oral                         | IGF-1 Receptor<br>Signal Inhibitor | Cancer     | Phase I / II<br>in US | In-House                   | Revision for priority of product<br>development portfolio in oncology<br>area |
|          |  | ⓄKHK2866<br>Injection                    | Anti-HB-EGF<br>Humanized Antibody  | Cancer     | Phase I<br>in US      | In-House                   |   |
|          |  | ⓄLY2523355<br>Litronesib<br>Injection    | M phase Kinesin<br>Eg5 Inhibitor   | Cancer     | Phase I<br>in JP      | In-House                   |   |